Your browser doesn't support javascript.
loading
Measurement of Free Plasma Concentrations of Beta-Lactam Antibiotics: An Applicability Study in Intensive Care Unit Patients.
Schießer, Selina; Hitzenbichler, Florian; Kees, Martin G; Kratzer, Alexander; Lubnow, Matthias; Salzberger, Bernd; Kees, Frieder; Dorn, Christoph.
  • Schießer S; Departments of Infection Prevention and Infectious Diseases and.
  • Hitzenbichler F; Departments of Infection Prevention and Infectious Diseases and.
  • Kees MG; Anaesthesiology.
  • Kratzer A; Hospital Pharmacy.
  • Lubnow M; Department of Internal Medicine II, University Hospital Regensburg.
  • Salzberger B; Departments of Infection Prevention and Infectious Diseases and.
  • Kees F; Institute of Pharmacy, University of Regensburg, Regensburg, Germany.
  • Dorn C; Institute of Pharmacy, University of Regensburg, Regensburg, Germany.
Ther Drug Monit ; 43(2): 264-270, 2021 04 01.
Article en En | MEDLINE | ID: mdl-33086362
ABSTRACT

BACKGROUND:

The antibacterial effect of antibiotics is linked to the free drug concentration. This study investigated the applicability of an ultrafiltration method to determine free plasma concentrations of beta-lactam antibiotics in ICU patients.

METHODS:

Eligible patients included adult ICU patients treated with ceftazidime (CAZ), meropenem (MEM), piperacillin (PIP)/tazobactam (TAZ), or flucloxacillin (FXN) by continuous infusion. Up to 2 arterial blood samples were drawn at steady state. Patients could be included more than once if they received another antibiotic. Free drug concentrations were determined by high-performance liquid chromatography with ultraviolet detection after ultrafiltration, using a method that maintained physiological conditions (pH 7.4/37°C). Total drug concentrations were determined to calculate the unbound fraction. In a post-hoc analysis, free concentrations were compared with the target value of 4× the epidemiological cut-off value (ECOFF) for Pseudomonas aeruginosa as a worst-case scenario for empirical therapy with CAZ, MEM or PIP/tazobactam and against methicillin-sensitive Staphylococcus aureus for targeted therapy with FXN.

RESULTS:

Fifty different antibiotic treatment periods in 38 patients were evaluated. The concentrations of the antibiotics showed a wide range because of the fixed dosing regimen in a mixed population with variable kidney function. The mean unbound fractions (fu) of CAZ, MEM, and PIP were 102.5%, 98.4%, and 95.7%, with interpatient variability of <6%. The mean fu of FXN was 11.6%, with interpatient variability of 39%. It was observed that 2 of 12 free concentrations of CAZ, 1 of 40 concentrations of MEM, and 11 of 23 concentrations of PIP were below the applied target concentration of 4 × ECOFF for P. aeruginosa. All concentrations of FXN (9 samples from 6 patients) were >8 × ECOFF for methicillin-sensitive Staphylococcus aureus.

CONCLUSIONS:

For therapeutic drug monitoring purposes, measuring total or free concentrations of CAZ, MEM, or PIP is seemingly adequate. For highly protein-bound beta-lactams such as FXN, free concentrations should be favored in ICU patients with prevalent hypoalbuminemia.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antibacterianos Límite: Adult / Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antibacterianos Límite: Adult / Humans Idioma: En Año: 2021 Tipo del documento: Article